This observational study aims to emulate a hypothetical pragmatic, multicenter, non-blinded clinical trial enrolling adult patients undergoing haploidentical hematopoietic stem cell transplantation (haplo-HSCT) with grafts derived from either cousin or sibiling donors.
The main research question is whether cousin donor-derived haplo-HSCT is associated with inferior clinical outcomes relative to sibling donor-derived haplo-HSCT.
Study participants consist of adult patients diagnosed with hematological malignancies who underwent cousin or sibiling haplo-HSCT between 2017 and 2024, and all eligible recipients will receive regular follow-up assessments.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Adult patients diagnosed with hematological malignancies, including acute leukemia (AL), chronic myeloid leukemia (CML), myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), and non-Hodgkin lymphoma (NHL)
* Receipt of first haploidentical hematopoietic stem cell transplantation between 2017 and 2024
* Documented exact date of transplantation available in medical charts
* Verifiable donor kinship classified as either cousin or sibiling
* Complete longitudinal follow-up data accessible for outcome assessment
Exclusion Criteria:
* Prior receipt of any form of hematopoietic stem cell transplantation
* An age difference of more than 18 years between the donor and recipient
* Failure of successful infusion of donor-derived hematopoietic stem cells following conditioning regimen
Primary outcome measure(s)
Overall survival — 2 years after transplantation estimated overall survival at 2 year
Graft-versus-host disease-free and relapse-free survival — 2 years after transplantation estimated graft-versus-host disease-free and relapse-free survival at 2 year
Cumulative incidence of acute graft-versus-host disease — 180 days after transplantation estimated cumulative incidence of acute graft-versus-host disease at 180 day
Cumulative incidence of chronic graft-versus-host disease — 2 years after transplantation estimated cumulative incidence of chronic graft-versus-host disease at 2 year
Trial sites (1)
Facility
City
Region
Status
The First Affiliated Hospital of Soochow University
Suzhou
Jiangsu
More The First Affiliated Hospital of Soochow University trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.